IPF PPF SSc-ILD Mechanism of Action Prescribing information Advancing PF Care Previous Next FACE IPF HEAD ON and modify disease progression by slowing lung function decline Identify Patients With RA-ILD Who Can Benefit From OFEV 26/10/2022 | Author: Boehringer Ingelheim Document ID: PC-SA-101935 | Expiry Date: 18/08/2026 PPF PPF Identify Patients With RA-ILD Who Can Benefit From OFEV SSc-ILD AE Management Animation - Management of diarrhea SSc-ILD AE Management Animation - Management of nausea and vomiting How to understand and manage limited cutaneous SSc-ILD Safety Profile of OFEV Treatment of patients with PPF and CTD-ILD How to recognize ILD and PPF in patients with CTD Related content Was this content helpful wrapper Did you find this content helpful? Like Dislike Like Unlike Wrapper Like Text Wrapper Could you share the aspects of the content you were satisfied with? We will continue to create good content with your feedback. I am generally satisfied with the content The content was of appropriate length The format of the content was good The information shared was relevant and sufficient Unlike text wrapper How can we create better content? Share your feedback: The content was not relevant to the topic The content was too long I think important points were skipped There were repeated topics Leave this field blank Home Respiratory | Therapeutic Area Ofev Efficacy Identify Patients With RA-ILD Who Can Benefit From OFEV
